Table 2. Characteristics of patients with NHL or CLL [31].
| Patient Characteristics | Age | Sex | Diagnosis | Previous therapies | Cytokines in CART culture | Time from last chemo. treatment | Pre-CART CTXA | DL | CAR+cells in product (%) | CAR+T cells/m2 admin. | No. of infusions | Best response |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P3 | 55 | M | FL/DLBCL | R-CHOP, R-ICE, R-BEAM/ASCT rituximab | IL-7/IL-15 | 16 wk | No | 3 | 85 | 1.7×108 | 6 | CR×6 wk |
| P4 | 69 | M | DLBCL | R-CHOP, R-BEA M/ASCT, R-bendamusti, ne/lenalidomide, R-ibrutinib, R-ESHAP, | IL-7/IL-15 | 14 d | No | 3 | 93 | 1.9×108 | 1 | NR |
A Low-dose CTX (12.5 mg/kg). admin., administered; chemo., chemotherapy; DL, dose level; MCL, mantle cell lymphoma; R-, Rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; 2CDA, cladribine; BEAM, carmustine, etoposide, cytarabine, melphalan; FCR, fludarabine, cyclophosphamide, Rituximab; ICE, ifosfamide, carboplatin, etoposide; TTR, paclitaxel, topotecan, Rituximab; hCVAD, hyperfractionated cyclophosphamide, vincristine, cytarabine, doxorubicin, dexamethasone; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; NR, no response.